BR112018070600A2 - receptores de células t - Google Patents
receptores de células tInfo
- Publication number
- BR112018070600A2 BR112018070600A2 BR112018070600A BR112018070600A BR112018070600A2 BR 112018070600 A2 BR112018070600 A2 BR 112018070600A2 BR 112018070600 A BR112018070600 A BR 112018070600A BR 112018070600 A BR112018070600 A BR 112018070600A BR 112018070600 A2 BR112018070600 A2 BR 112018070600A2
- Authority
- BR
- Brazil
- Prior art keywords
- tcr
- cells
- cell receptors
- tcrs
- nucleic acids
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
a presente invenção refere-se a receptores de células t (tcrs) que se ligam a peptídeo restrito hla-a*0201 gvydgeehsv (seq id nº: 1) derivados da proteína mage-b2. os tcrs da presente invenção demonstram excelentes perfis de especificidade para este epítopo mage. são também proporcionados ácidos nucleicos que codificam o tcr, células manipuladas para apresentar o tcr, células que albergam os vetores de expressão que codificam o tcr e composições farmacêuticas compreendendo os tcrs, ácidos nucleicos ou células da invenção.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201606172 | 2016-04-08 | ||
PCT/EP2017/058576 WO2017174822A1 (en) | 2016-04-08 | 2017-04-10 | T cell receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018070600A2 true BR112018070600A2 (pt) | 2019-02-05 |
Family
ID=58701591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018070600A BR112018070600A2 (pt) | 2016-04-08 | 2017-04-10 | receptores de células t |
Country Status (14)
Country | Link |
---|---|
US (2) | US20190135892A1 (pt) |
EP (1) | EP3440102A1 (pt) |
JP (2) | JP7179616B2 (pt) |
KR (1) | KR20190059874A (pt) |
CN (2) | CN110023330B (pt) |
AU (2) | AU2017248120B2 (pt) |
BR (1) | BR112018070600A2 (pt) |
CA (1) | CA3020530A1 (pt) |
IL (1) | IL262146A (pt) |
MX (1) | MX2018012265A (pt) |
RU (1) | RU2018138836A (pt) |
SG (1) | SG11201808709VA (pt) |
WO (1) | WO2017174822A1 (pt) |
ZA (1) | ZA201806865B (pt) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA49157A (fr) | 2014-12-23 | 2021-06-02 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
EP3440104B2 (en) * | 2016-04-08 | 2023-06-14 | Adaptimmune Limited | T cell receptors |
JP7240176B2 (ja) | 2016-04-08 | 2023-03-15 | アダプティミューン・リミテッド | T細胞受容体 |
WO2019069125A1 (en) | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
WO2019133443A1 (en) * | 2017-12-28 | 2019-07-04 | Janux Therapeutics, Inc. | Modified t cell receptors |
JP7469807B2 (ja) * | 2018-04-19 | 2024-04-17 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Mage-b2特異性を有するt細胞受容体およびその使用 |
MX2021003051A (es) * | 2018-09-14 | 2021-05-27 | Immatics Biotechnologies Gmbh | Metodo para el cribado de alto desempe?o de la afinidad mhc-peptido para ligandos tcr mediante complejos mhc libres de peptidos estabilizados. |
USD998170S1 (en) * | 2019-04-10 | 2023-09-05 | Inveox Gmbh | Sample container |
CN110172091B (zh) * | 2019-04-28 | 2020-04-03 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
BR112021026376A2 (pt) | 2019-06-25 | 2022-05-10 | Gilead Sciences Inc | Proteínas de fusão flt3l-fc e métodos de uso |
CN114555791A (zh) | 2019-08-13 | 2022-05-27 | 伦敦国王学院 | Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞 |
AU2021219668A1 (en) | 2020-02-14 | 2022-08-25 | Gilead Sciences, Inc. | Antibodies and fusion proteins that bind to CCR8 and uses thereof |
JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Mageb2結合構築物 |
TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
TW202330504A (zh) | 2021-10-28 | 2023-08-01 | 美商基利科學股份有限公司 | 嗒𠯤—3(2h)—酮衍生物 |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867283B2 (en) * | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
PL208712B1 (pl) | 2001-08-31 | 2011-05-31 | Avidex Ltd | Rozpuszczalny receptor komórek T (sTCR), rozpuszczalna αβ-postać receptora komórek T (sTCR), wielowartościowy kompleks receptora komórek T (TCR), sposób wykrywania kompleksów MHC-peptyd, środek farmaceutyczny zawierający sTCR i/lub wielowartościowy kompleks TCR, cząsteczka kwasu nukleinowego, wektor, komórka gospodarz, sposób otrzymywania całości lub części łańcucha α TCR albo całości lub części łańcucha β TCR, sposób otrzymywania rozpuszczalnego receptora komórek T (sTCR), sposób otrzymywania rozpuszczalnej αβ-postaci receptora komórek T (sTCR) oraz sposób wykrywania kompleksów MHC-peptyd |
BRPI0924556A2 (pt) * | 2009-06-09 | 2015-06-30 | Vaxon Biotech | "identificação, otimização e uso de epítopos hla-b*0702 compartilhados para imunoterapia" |
SG11201500423TA (en) * | 2012-07-27 | 2015-02-27 | Univ Illinois | Engineering t-cell receptors |
EP3440104B2 (en) * | 2016-04-08 | 2023-06-14 | Adaptimmune Limited | T cell receptors |
JP7240176B2 (ja) * | 2016-04-08 | 2023-03-15 | アダプティミューン・リミテッド | T細胞受容体 |
DK3440105T3 (da) * | 2016-04-08 | 2022-06-13 | Immunocore Ltd | T-cellereceptorer |
-
2017
- 2017-04-10 SG SG11201808709VA patent/SG11201808709VA/en unknown
- 2017-04-10 MX MX2018012265A patent/MX2018012265A/es unknown
- 2017-04-10 RU RU2018138836A patent/RU2018138836A/ru unknown
- 2017-04-10 CN CN201780031672.0A patent/CN110023330B/zh active Active
- 2017-04-10 CN CN202311577769.5A patent/CN117603339A/zh active Pending
- 2017-04-10 CA CA3020530A patent/CA3020530A1/en active Pending
- 2017-04-10 KR KR1020187032021A patent/KR20190059874A/ko not_active Application Discontinuation
- 2017-04-10 AU AU2017248120A patent/AU2017248120B2/en active Active
- 2017-04-10 WO PCT/EP2017/058576 patent/WO2017174822A1/en active Application Filing
- 2017-04-10 BR BR112018070600A patent/BR112018070600A2/pt unknown
- 2017-04-10 JP JP2018552696A patent/JP7179616B2/ja active Active
- 2017-04-10 EP EP17723015.8A patent/EP3440102A1/en active Pending
-
2018
- 2018-10-04 IL IL262146A patent/IL262146A/en unknown
- 2018-10-08 US US16/154,161 patent/US20190135892A1/en not_active Abandoned
- 2018-10-15 ZA ZA2018/06865A patent/ZA201806865B/en unknown
-
2022
- 2022-01-12 US US17/574,152 patent/US20220127327A1/en active Pending
- 2022-07-04 JP JP2022107704A patent/JP7437452B2/ja active Active
- 2022-10-20 AU AU2022256181A patent/AU2022256181A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017248120A1 (en) | 2018-11-22 |
JP2022153399A (ja) | 2022-10-12 |
MX2018012265A (es) | 2019-02-07 |
WO2017174822A1 (en) | 2017-10-12 |
AU2022256181A1 (en) | 2022-11-24 |
RU2018138836A3 (pt) | 2020-07-30 |
US20190135892A1 (en) | 2019-05-09 |
CA3020530A1 (en) | 2017-10-12 |
JP7179616B2 (ja) | 2022-11-29 |
CN110023330B (zh) | 2023-12-12 |
JP7437452B2 (ja) | 2024-02-22 |
RU2018138836A (ru) | 2020-05-12 |
ZA201806865B (en) | 2021-04-28 |
CN110023330A (zh) | 2019-07-16 |
IL262146A (en) | 2018-11-29 |
SG11201808709VA (en) | 2018-11-29 |
AU2017248120B2 (en) | 2022-07-21 |
KR20190059874A (ko) | 2019-05-31 |
JP2019516355A (ja) | 2019-06-20 |
CN117603339A (zh) | 2024-02-27 |
EP3440102A1 (en) | 2019-02-13 |
US20220127327A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018070600A2 (pt) | receptores de células t | |
BR112018070625A2 (pt) | receptores de células t | |
BR112018070637A2 (pt) | receptores de células t | |
BR112017007202A2 (pt) | receptores de célula t | |
BR112018070187A8 (pt) | receptores quiméricos para flt3 e seus métodos de uso | |
BR112018070260A2 (pt) | receptores quiméricos e métodos de uso dos mesmos | |
UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
NZ715038A (en) | T cell receptors | |
CA3062698A1 (en) | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof | |
BR112018071612A2 (pt) | polipeptídeos biespecíficos inovadores contra cd137 | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
CL2012002095A1 (es) | Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa | |
WO2015061416A3 (en) | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use | |
WO2016130628A8 (en) | Griffithsin mutants | |
WO2015107363A3 (en) | Mycobacterial antigen composition | |
BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
EP4269562A3 (en) | Antigen binding molecules and methods of use thereof | |
BR112017014737A2 (pt) | formulação de peptídeos inibidores de mk2 | |
BR112019007343A2 (pt) | sequência de nucleotídeos expressando uma proteína de ancoragem de exossomo para uso como vacina | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
CL2020002373A1 (es) | Composición de vacuna que comprende un péptido aislado de piojo de mar; uso de la vacuna para para prevenir o controlar una infestación de piojos de mar en un salmónido; vector; célula hospedadora (divisional de la solicitud no. 201900422). | |
EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
PE20190967A1 (es) | Aislados modificados de streptomyces fungicidicus y su uso | |
PH12019502717A1 (en) | Recombinant robo2 proteins, compositions, methods and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25G | Requested change of headquarter approved |
Owner name: ADAPTIMMUNE LIMITED (GB) |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |